Amgen Inc (AMGN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Amgen Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 385.20 $ — 94% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 7.3% below the current price.
- Consensus
- Sell
- Analyst Ratings
- 32
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 22.35 | 21.70 – 23.11 | 37,735 | 2.3% | 33 |
| 12/31/2027 | 23.44 | 21.43 – 25.27 | 38,661 | 4.9% | 31 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 5.60 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.16 | -18.60 | 9,086 | 10.90 | 6.90 | 4,771 | 4,400 |
| 2025: Q1 | 3.20 | – | 8,149 | 9.40 | 21.20 | 1,391 | 980 |
| 2025: Q2 | 2.65 | 92.00 | 9,167 | 9.30 | 15.60 | 2,280 | 1,911 |
| 2025: Q3 | 5.93 | 13.60 | 9,557 | 12.40 | 33.70 | 4,684 | 4,248 |
| 2025: Q4 | 2.45 | 112.20 | 9,896 | 8.90 | 13.50 | 1,603 | 961 |
| 2026: Q1 | 3.34 | 4.60 | 8,618 | 5.80 | 21.10 | 2,189 | 1,477 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 22,991 | 9,794 | 7,722 | 10.24 | 10,354 | 29,875 | 77,626 |
| 2017 | 22,849 | 9,973 | 1,979 | 2.69 | 11,177 | 25,241 | 79,954 |
| 2018 | 23,747 | 10,263 | 8,394 | 12.62 | 11,296 | 12,500 | 66,416 |
| 2019 | 23,362 | 9,674 | 7,842 | 12.88 | 9,150 | 9,673 | 59,707 |
| 2020 | 25,424 | 9,139 | 7,264 | 12.31 | 10,497 | 9,409 | 62,948 |
| 2021 | 25,979 | 7,639 | 5,893 | 10.28 | 9,261 | 6,700 | 61,165 |
| 2022 | 26,323 | 9,566 | 6,552 | 12.11 | 9,721 | 3,661 | 65,121 |
| 2023 | 28,190 | 7,897 | 6,717 | 12.49 | 8,471 | 6,232 | 97,154 |
| 2024 | 33,424 | 7,258 | 4,090 | 7.56 | 11,490 | 5,877 | 91,839 |
| 2025 | 36,741 | 10,676 | 7,711 | 14.23 | 9,958 | 8,658 | 90,586 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Amgen Inc. erforscht, entwickelt, fertigt und liefert weltweit humanmedizinische Therapeutika.
| Employees | 31,500 |
|---|---|
| Headquarters | Thousand Oaks, CA |
| Address | One Amgen Center Drive, 91320-1799 Thousand Oaks, United States |
| Phone | 805 447 1000 |
| Website | amgen.com |
| IPO Date | 17. Jun 1983 |
| ISIN | US0311621009 |
| Stock Split | 2:1 on 11/22/1999 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert A. Bradway | Chairman & CEO | 1963 |
| Peter H. Griffith | Executive VP & CFO | 1959 |
| Murdo Gordon | Executive Vice President of Global Markets and Policy | 1967 |
| James E. Bradner M.D. | EVP of Research & Development, Artificial Intelligence and Data | 1972 |
| Esteban Santos | Executive Vice President of Operations | 1968 |
| Matthew C. Busch | Chief Accounting Officer & VP of Finance | 1975 |
| Sean Bruich | SVP & Chief Technology Officer | – |
| Scott Skellenger | Senior VP & Chief Information Officer | – |
| Howard Y. Chang M.D., Ph.D. | Senior VP of Global Research & Chief Scientific Officer | – |
| Casey Capparelli | Executive Director of Investor Relations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.